Medindia
Unlock the benefits of registration Click Here
Medindia » Health In Focus

Long-term Proton Pump Inhibitor Use Associated With Stomach Cancer

by Simi Paknikar on November 1, 2017 at 6:54 PM
Listen to this News

Highlights:

The prolonged use of proton pump inhibitors following treatment for H. pylori infection of the stomach has been linked to an increased risk of stomach cancer. The study from Hong Kong was published in BMJ Gut.


Proton pump inhibitors, which include drugs like omeprazole, lansoprazole and pantoprazole, have been used for several years for the treatment of stomach ulcers. They bring about their effect by blocking a target called the proton pump in the inner lining of the stomach, thereby reducing the acid secretion by the stomach. They are included in the treatment regimen of Helicobacter pylori infection.

‘The prolonged use of proton pump inhibitors, drugs used to reduce gastric acidity, has been linked to the development of stomach cancer’

Helicobacter pylori or H. pylori is a bacterium that attaches to the inner layer of the stomach. Most patients with H. pylori in their stomachs do not suffer from any symptoms. Some people suffer from gastritis or stomach ulcers and even run a small risk of suffering from stomach cancer. The infection is treated with specific drug regimens that contain a proton pump inhibitor, at least two antibacterials and sometimes an additional drug.

Physicians sometimes advise the long-term use of proton pump inhibitors to reduce gastric acidity after the treatment for H. pylori infection. Scientists gathered data from patients who received treatment for H. pylori infection and were then prescribed either proton pump inhibitors or alternative acid-reducing drugs called H2 blockers over prolonged durations. H2 blockers include drugs like ranitidine, famotidine and nizatidine. The study population included 63,397 adults who were followed up for an average period of 7.5 years. The scientists found that:

Most patients took H2 blockers, while 5% took proton pump inhibitors for an average of around 3 years.

The risk of stomach cancer was more than double in the group taking proton pump inhibitors, while the increased risk was not noted in those taking H2 blockers

The risk increased with:

Since H. pylori was absent in the stomach due to prior treatment, the risk of stomach cancer due to H. pylori was eliminated in the study. The study was, however, not designed to establish whether proton pump inhibitors cause stomach cancer. Further studies designed to specifically answer the question are the need of the hour.

Reference:

  1. Cheung KS, Chan EW, Wong AYS, et al Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study Gut. doi: http://dx.doi.org/10.1136/gutjnl-2017-314605
Source: Medindia

Cite this Article

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Simi Paknikar. (2017, November 01). Long-term Proton Pump Inhibitor Use Associated With Stomach Cancer. Medindia. Retrieved on Jan 04, 2025 from https://www.medindia.net/news/healthinfocus/long-term-proton-pump-inhibitor-use-associated-with-stomach-cancer-174265-1.htm.

  • MLA

    Simi Paknikar. "Long-term Proton Pump Inhibitor Use Associated With Stomach Cancer". Medindia. Jan 04, 2025. <https://www.medindia.net/news/healthinfocus/long-term-proton-pump-inhibitor-use-associated-with-stomach-cancer-174265-1.htm>.

  • Chicago

    Simi Paknikar. "Long-term Proton Pump Inhibitor Use Associated With Stomach Cancer". Medindia. https://www.medindia.net/news/healthinfocus/long-term-proton-pump-inhibitor-use-associated-with-stomach-cancer-174265-1.htm. (accessed Jan 04, 2025).

  • Harvard

    Simi Paknikar. 2017. Long-term Proton Pump Inhibitor Use Associated With Stomach Cancer. Medindia, viewed Jan 04, 2025, https://www.medindia.net/news/healthinfocus/long-term-proton-pump-inhibitor-use-associated-with-stomach-cancer-174265-1.htm.

View Non AMP Site | Back to top ↑